|

An Open Letter to Officials of the National Institute of Mental Health

An Open Letter to Officials of the National Institute of Mental Health Fri, 30 Apr 2004 ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure https://ahrp.org From: Vera Hassner Sharav, President David Cohen, Ph.D. Secretary The ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP)     To: Thomas Insell, MD,…

Suicide Rate Unchanged in 10 Years–JAMA / AMA Considers Stand Against Warning Labels on Antidepressants

Suicide Rate Unchanged in 10 Years–JAMA / AMA Considers Stand Against Warning Labels on Antidepressants Thu, 9 Jun 2005 A major report in the Journal of the American Medical Association shatters all claims about the effectiveness of antidepressants as a treatment for the prevention of suicide. A comparison of the…

Next Phase in Psychiatry? Or, NIMH Effort to Rescue Bad Drugs – WSJ

Next Phase in Psychiatry? Or, NIMH Effort to Rescue Bad Drugs – WSJ Fri, 29 Jul 2005 The Wall Street Journal uncritically reported: “The results of the largest studies ever conducted of depression and schizophrenia will be released in coming months, potentially transforming the way patients are treated and shaking…

Glaxo chief executive angry over NYS AG lawsuit – Telegraph

Glaxo chief executive angry over NYS AG lawsuit – Telegraph Tue, 8 Jun 2004 The significance of the lawsuit filed by NYS Attorney General, Eliot Spitzer, has infuriated Jean-Pierre Garnier, GlaxoSmithKline’s CEO. As Money.Telegraph (UK) reports (below), the AG suit carries a significance beyond the money sought. “Reputationally, however, the…

UK Health Dept/ British Prime Minister/ Issue Statement Warning No PAXIl for children!

UK Health Dept/ British Prime Minister/ Issue Statement Warning No PAXIl for Children! Tue, 10 Jun 2003 UK GOVERNMENT STATEMENT: Press release: reference 2003/0223 Tuesday 10th June 2003 Related Story: GlaxoSmithKline discloses link to serious undesirable effects in depressed children and adolescents under age 18 SEROXAT MUST NOT BE USED…

Conflicts of Interest policy – New York Times

Conflicts of Interest policy – New York Times Sun, 28 Mar 2004 To: ‘Executive-editor@nytimes’; ‘gcollins@nytimes’; ‘arosenthal@nytimes’; ‘pboffey@nytimes’; ‘lchang@nytimes’; ‘oped@nytimes’ Cc: ‘Daniel Okrent’ ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure https://ahrp.org FYI Friday’s New York Times included the following Editor’s Note on the paper’s Op Ed page:…

Drug safety Hearings-Sept-Congress/ FDA – Lilly Plans to Disclose Data

Drug safety Hearings-Sept-Congress/ FDA – Lilly Plans to Disclose Data Tue, 3 Aug 2004 A hearing about the possible connection between suicide and antidepressant drugs will be held on Aug 4, by the California Senate by Sen. Tom Torkalson, chairman of the Senate Task Force on Youth and Workplace Wellness…

ADHD drug Cylert withdrawn from market due to Liver Toxicity

ADHD drug – Cylert withdrawn from market due to Liver Toxicity, a Major Risk of Psychotropic Drugs Tue, October 25, 2005 The FDA announced that another drug prescribed for ADHD–Cylert–was removed from the US market for safety reasons. On September 25, 2005, the Associated Press reported: “Eli Lilly said it…

Meta-Analysis: Efficacy & Safety of Antidepressants for Children – Brit Medical Journal

Meta-Analysis: Efficacy & Safety of Antidepressants for Children – Brit Medical Journal Sat, 10 Apr 2004 As news of skyrocketing prescribing of antidepressants for children–especially in preschool children–hit the news waves around the world, a major meta-analysis of the 5 published pediatric antidepressant studies was published in the British Medical…

When Doctors Learn, Drug Firms Often Pay the Tab – Philly Inquirer

When Doctors Learn, Drug Firms Often Pay th eTab – Philly Inquirer Wed, 8 Jun 2005 The Philadelphia Inquirer reports about the blinders that academic medical institutions and physicians (in this instance psychiatrists) put on pretending not to know that they have surrendered the integrity of medicine and medical education…